Volume 19, Number 10—October 2013
Dispatch
New Clonal Strain of Candida auris, Delhi, India
Table 1
Results of In vitro antifungal susceptibility testing of 12 Candida auris isolates originating from fungemia patients in 2 hospitals, Delhi, India, 2009–2011
MIC, mg/L* |
Drug† |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
AMB |
FLU |
ITC |
VRC |
ISA |
POS |
FC |
CAS |
MFG |
AFG |
|
MIC50 | 0.25 | 32 | 0.125 | 0.5 | 0.125 | 0.125 | 0.125 | 0.25 | 0.06 | 0.25 |
MIC90 | 0.5 | 64 | 0.25 | 1 | 0.25 | 0.25 | 0.125 | 0.25 | 0.125 | 0.5 |
GM | 0.33 | 28.5 | 0.15 | 0.39 | 0.10 | 0.12 | 0.125 | 0.23 | 0.072 | 0.26 |
Range | 0.25–1 | 16–64 | 0.125–0.25 | 0.125–1 | <0.015–0.25 | 0.06–0.25 | 0.125 | 0.125–0.25 | 0.06–0.125 | 0.125–0.5 |
*MIC50, 50% minimum inhibitory concentration; MIC90, 90% minimum inhibitory concentration; GM, geometric mean of MICs.
†AMB, amphotericin B; FLU, fluconazole; ITC, itraconazole; VRC, voriconazole; ISA, isavuconazole; POS, posaconazole; FC, flucytosine; CAS, caspofungin; MFG, micafungin; AFG, anidulafungin.